ResultsIQ

ResultsIQ › Latest results › Gaudium IVF and Women Health Limited

Gaudium IVF and Women Health Limited Q2 FY27 results deck summary

NSE: GAUDIUMIVF · BSE: 544709

Results deck of 15 Nov 2026, summarised by AI from the filing.

Consolidated EBITDA margin was 36.00% (Q2 FY26: 43.37%) and PAT margin 25.16% (Q2 FY26: 29.56%) on new-hub costs.

Key takeaways

  1. Margin pressure Consolidated EBITDA margin was 36.00% (Q2 FY26: 43.37%) and PAT margin 25.16% (Q2 FY26: 29.56%) on new-hub costs.
  2. Sequential rebound Consolidated revenue rose to ₹3,741.11 lakh in Q2 FY27 from ₹1,937.66 lakh in Q1 FY27, and PAT to ₹941.31 lakh from ₹177.59 lakh.
  3. Expansion South Delhi and Gurgaon hubs were inaugurated in FY27, Nagpur is launching soon, and seven upcoming hubs are planned for FY27.
  4. Licence risk The South Delhi Hub centre is ready but its licence approval is still awaited.

Original filing on BSE

Gaudium IVF and Women Health Limited Q2 FY27 results

As filed: Revenue ₹37.4 cr, EBITDA ₹13.5 cr, PAT ₹9.4 cr, EBITDA margin 36.0%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹37.4 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹19.4 cr, EBITDA ₹2.4 cr, PAT ₹1.8 cr, EBITDA margin 12.5%. Not scored. Too small to score: quarter revenue ₹19.4 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −6.4% in 29 days (Nifty 500: −3.3%).
  • Q4 FY26: Revenue ₹30.4 cr, EBITDA ₹12.2 cr, PAT ₹8.4 cr, EBITDA margin 40.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹30.4 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −7.0% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹24.5 cr, EBITDA ₹6.6 cr, PAT ₹3.6 cr, EBITDA margin 26.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹24.5 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +2.2% in 30 days (Nifty 500: +4.3%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gaudium IVF and Women Health Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.